- Analytics
- News and Tools
- Market News
- UK: Oral COVID-19 antiviral, Paxlovid, approved by MHRA
UK: Oral COVID-19 antiviral, Paxlovid, approved by MHRA
The UK's Medicines and Healthcare Products Regulator Agency (MHRA) announced on Friday that they have approved the oral COVID-19 antiviral, Paxlovid, as reported by Reuters.
Key takeaways
"New combination treatment is for people with mild to moderate COVID-19 who are at high risk of developing severe COVID-19."
"Too early to know whether Omicron variant has any impact on Paxlovid's effectiveness."
"Number of hospitalisations and deaths were 0.8% (3 out of 389) in the Paxlovid group compared with 7% (27 out of 385) in the placebo group."
"The two active substances of Paxlovid come as separate tablets that are packaged together and taken together, twice a day by mouth for 5 days."
"MHRA is proactively working with the company to establish the effectiveness of Paxlovid against omicron."
"Paxlovid authorised for use in people aged 18 & above who have mild to moderate COVID-19 infection & at least 1 risk factor for developing severe illness."
"Based on clinical trial data, Paxlovid is most effective when taken during the early stages of infection."
"Before Paxlovid is prescribed, MHRA is advising that patients' current medications should be carefully reviewed."
Market reaction
This headline doesn't seem to be having a noticeable impact on risk sentiment.
© 2000-2024. All rights reserved.
This site is managed by Teletrade D.J. LLC 2351 LLC 2022 (Euro House, Richmond Hill Road, Kingstown, VC0100, St. Vincent and the Grenadines).
The information on this website is for informational purposes only and does not constitute any investment advice.
The company does not serve or provide services to customers who are residents of the US, Canada, Iran, The Democratic People's Republic of Korea, Yemen and FATF blacklisted countries.
Making transactions on financial markets with marginal financial instruments opens up wide possibilities and allows investors who are willing to take risks to earn high profits, carrying a potentially high risk of losses at the same time. Therefore you should responsibly approach the issue of choosing the appropriate investment strategy, taking the available resources into account, before starting trading.
Use of the information: full or partial use of materials from this website must always be referenced to TeleTrade as the source of information. Use of the materials on the Internet must be accompanied by a hyperlink to teletrade.org. Automatic import of materials and information from this website is prohibited.
Please contact our PR department if you have any questions or need assistance at pr@teletrade.global.
Bank transfers
